OCA
PALI icon

Octagon Capital Advisors’s Palisade Bio PALI Stock Holding History

Octagon Capital Advisors’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.5M Hold
10,276,317
– – 1.93% 14
2026
Q1 		$18M Buy
10,276,317
+708,419
+7% +$1.29M 1.99% 16
2025
Q4 		$22.5M Buy
+9,567,898
New +$18.4M 2.73% 13

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Octagon Capital Advisors's PALI Position: Q2 2026 in Review

Octagon Capital Advisors held its Palisade Bio (PALI) position steady in Q2 2026 at 10,276,317 shares worth $21.5M. The position accounts for 1.93% of the portfolio, ranked #14.

Octagon Capital Advisors first reported a position in PALI in Q4 2025 and has held it in 3 quarters since. The position peaked at $22.5M in Q4 2025. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Octagon Capital Advisors held 10,276,317 shares of Palisade Bio worth $21.5M as of Q2 2026.
  • Octagon Capital Advisors left its Palisade Bio share count unchanged in Q2 2026.
  • Palisade Bio made up 1.93% of Octagon Capital Advisors's portfolio in Q2 2026, its #14 holding.
  • Octagon Capital Advisors first reported a position in Palisade Bio in Q4 2025 and has held it in 3 quarters since.
  • Octagon Capital Advisors's Palisade Bio position peaked at $22.5M in Q4 2025.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.